“(Reuters) — Neumora Therapeutics, a biopharmaceutical firm backed by biotech Amgen and Japan’s SoftBank, on Friday filed for an initial public offering of its shares in New York.

The filing comes at a time of renewed investor interest in IPOs following a flurry of deals in the United States and European markets, which have over the last year seen many high-profile startups shelve their listing plans due to market volatility.

Neumora’s lead drug candidate navacaprant is a potential oral treatment of major depressive disorder. The company anticipates results from the first of its three late-stage trials of the drug in the second half of 2024…”

Continue reading at the original source, linked here.